Form 4 for FBIO Fortress Biotech, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-01 · accession 0001294517-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | 2026-01-01 | FBIO | Hoenlein Malcolm | Dir | A - Grant | $0.00 | +27.3K | 115.7K | +31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.001 | 2026-01-01 | A | A | 27,322 | $0.00 | 115,747 | D | — | — | (F1) The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. (F2) Total holdings include 52,507 shares underlying deferred restricted stock units. |